Ionis Pharmaceuticals, Inc. filed a current report on Form 8-K on September 4, 2026, disclosing that the U.S. Food and Drug Administration approved ZANVASTRO (zilganersen) on September 3, 2026, for the treatment of Alexander disease in pediatric and adult patients.
Key Highlights
- First approved treatment: ZANVASTRO is described in the filing as "the first and only disease modifying treatment" for Alexander disease (AxD).
- Pivotal study primary endpoint met: In individuals aged 5 and older, ZANVASTRO 50 mg showed a least square mean difference of 33.3% (p=0.041) in gait speed versus control at Week 61, as measured by the 10-Meter Walk Test.
- Dosing and administration: ZANVASTRO 50 mg is administered quarterly as an intrathecal injection.
- Priority Review Voucher granted: The FDA granted Ionis a Priority Review Voucher in connection with this approval.
- International licensing: In June 2026, Ionis entered into a license agreement with Recordati for exclusive rights to develop and commercialize zilganersen in all countries outside the U.S.
- Regulatory submissions planned: Regulatory submissions in Europe and Japan are expected in 2027, according to the filing.
FDA Approval of ZANVASTRO and the Pivotal Study Results Disclosed by Ionis
According to the filing, Ionis Pharmaceuticals (NASDAQ:IONS) announced the FDA approval of ZANVASTRO (zilganersen) for Alexander disease, an "ultra-rare, progressive and often fatal neurological disorder" affecting approximately 1 in 1 to 3 million people worldwide. The filing states that, until this approval, treatment of AxD had been "primarily limited to managing symptoms." ZANVASTRO is described as an RNA-targeted medicine designed to reduce the production of glial fibrillary acidic protein (GFAP), addressing what the filing characterizes as the underlying disease mechanism of AxD.
The FDA approval was based on results from a pivotal study, as described in the filing. The study met its primary endpoint in individuals aged 5 and older, with ZANVASTRO 50 mg demonstrating "statistically significant and clinically meaningful stabilization of gait speed" compared to control at Week 61, with a least square mean difference of 33.3% and a p-value of 0.041. In patients aged 2 to 4 years, the filing reports improvement in gross motor function as measured by the Gross Motor Function Measure-88 compared to control at Week 61. The filing also states that secondary and exploratory endpoint results "consistently favored ZANVASTRO," and that serious treatment-emergent adverse events occurred less frequently in the ZANVASTRO group compared to control.
The filing notes that ZANVASTRO will be available in the U.S. "in the coming weeks." On the international front, Ionis disclosed a license agreement signed in June 2026 with Recordati, headquartered in Italy, granting Recordati exclusive rights to develop and commercialize zilganersen outside the U.S. The filing also notes that the FDA granted Ionis a Priority Review Voucher with this approval. The filing contains forward-looking statements, which Ionis identified as subject to risks and uncertainties described in its annual report on Form 10-K for the year ended December 31, 2025, and its most recent Form 10-Q.
What Was Disclosed
Ionis Pharmaceuticals disclosed the September 3, 2026 FDA approval of ZANVASTRO (zilganersen) for Alexander disease in pediatric and adult patients, along with pivotal study data, a Priority Review Voucher grant, and a licensing agreement with Recordati for rights outside the U.S.




Please wait processing your request...